Market event · the 2026 migration
After Hims: the compounded tirzepatide migration guide — records, bridge timing, and the tier-labeled 2026 field
In March 2026, the biggest consumer brand in compounded weight-loss medicine exited compounded tirzepatide as part of a settlement — semaglutide programs continued (around $175/month as of this writing, alongside a branded oral lane), but tirzepatide patients got a hard stop and a market’s worth of migration offers, not all of them honest. The move has three clocks running at once. Clock one, your records: export everything now while portal access is calm — dose history, last-fill date, the terms in force, your cancellation confirmation — because every downstream step (new intake, bridge timing, any billing dispute) runs on that file. Clock two, the bridge: tirzepatide’s ~five-day half-life gives a missed-dose window of about four days past schedule, while a new provider’s corridor commonly runs two to three weeks — so the intake starts before the last dose runs out, not after. Clock three, the field: 2026 re-verification moved almost every number people remember — the audited flat floor sits at $139–$169/month tirzepatide, dose-proof, month-to-month; the strongest on-record independent runs $133 with open terms questions; no-commitment lanes at the famous names now price near $449; and self-published entrants at $99–$149 remain verification-pending. The full tier-labeled map, the seven-day plan, and the migration-offer red flags are below. (Compounded formulations use the same active ingredient as brand tirzepatide but are not FDA-approved as finished drugs.)
What actually happened — and what didn’t
The facts worth carrying: as part of a March 2026 settlement, the brand ended its compounded tirzepatide offering. It did not exit weight-loss care — compounded semaglutide continued (recently around $175/month flat), and a branded oral semaglutide lane launched alongside it — which matters because the company’s own retention play is a molecule switch, not a refund: departing tirzepatide patients get offered semaglutide continuity in-house. That’s a legitimate option with a real trade — the head-to-head trial gap between the molecules ran roughly six percentage points of body weight in treatment-naive populations — and the switching file covers that decision on its own terms. This guide covers the other path: staying on tirzepatide by moving providers. What also didn’t happen: tirzepatide itself didn’t become unavailable, compounding law didn’t change that week, and your clinical history didn’t reset — the disruption is contractual and logistical, which is exactly the kind this site’s files were built for.
The records run — do this while the portal is boring
Run the export ritual against the account this week, whether or not you’ve chosen a destination: dose history (every strength and date — the artifact a new prescriber needs to continue rather than restart your titration), the last-fill date and remaining supply count (bridge math’s raw inputs), the terms version in force (PDF it — refund and wind-down language gets adjudicated on what you can produce), billing history, and — if you cancel rather than convert — the cancellation confirmation with its timestamp. Two Hims-specific notes: first, patients mid-prepay at the exit have a genuine pro-ration question — the refund taxonomy sorts which class your plan sits in, and the ladder exists if a promised remainder stalls; second, portal messages announcing the transition are terms-relevant exhibits — screenshot them into the same folder. None of this presumes bad faith. All of it presumes the thing paperwork always presumes: memory fades, portals close, and files don’t.
Bridge timing — the only genuinely urgent part
Tirzepatide’s half-life is about five days, and standard missed-dose guidance allows roughly a four-day window past the scheduled day before the labels say skip-and-resume — which means a migration planned around your remaining supply is calm, and one started after the last pen is empty becomes a restart, complete with re-titration from the bottom. Work backward: count doses on hand, subtract the two-to-three-week corridor a new provider’s intake-approval-compounding-shipping sequence typically takes, and you get your start-the-intake-by date — for most people reading this, that date is now. Bring the exported dose history to the new intake so the prescriber can continue your current maintenance dose rather than defaulting to a starter ladder; expect a legitimate provider to verify rather than rubber-stamp (that friction is a feature); and if the math says a gap is unavoidable, loop the new prescriber on timing rather than stretching doses solo — interval improvisation under deadline pressure is how four-day windows become four-week gaps.
The 2026 tirzepatide field — tier-labeled, corrected, dated
Every number below reflects this year’s re-verification pass, because migration shopping on remembered prices is how people land in $449 surprises. Audited tier (live checkout walked, figure dated): the flat floor is $139–$169/month for tirzepatide depending on term — $169 month-to-month stepping to $139 on the twelve-month track ($1,668 year-one) — dose-proof (the price doesn’t climb as maintenance doses do, which is precisely the failure mode that makes dose-tier migrations expensive later), month-to-month exit rights with thirty-day written cancellation, and the audit trail published: the audited tirzepatide floor, dated ↗ (compounded; same active ingredient as brand; not FDA-approved). On-record tier (published price captured, checkout not audited): the strongest independent figure is $133/month with a no-subscription framing — genuinely competitive, with open questions on terms depth that a ten-minute terms read settles before you rely on it; a flat $249.99 across 2–15 mg occupies the premium-flat lane honorably. The corrected famous names: the no-commitment tirzepatide lane at the best-known telehealth brand now runs about $449/month month-to-month (its ~$197/month figure requires a ~$2,364 prepay flagged non-refundable — read the taxonomy before wiring that). Verification-pending tier: self-published $99–$149 entrants exist and might be excellent — they carry pending labels here until independent verification, and the new-entrant audit shows exactly how to promote one yourself. The brand lane: direct-pay brand tirzepatide starts near $449+ at maintenance strengths (entry vials lower), while covered brand with a savings card can land near $25/month — which is why the first migration step is always a five-minute coverage check, because no compounded price beats a covered one.
Migration-offer red flags — the patterns that follow every exit
Market exits summon predators, and the 2026 wave ran true to form. The urgency prepay: “lock a year at this price before spots fill” aimed at people with a four-day pharmacology window — forfeiture-class prepays dressed as rescue; the taxonomy’s rule holds double under deadline: never prepay what you can’t afford to abandon. The unnamed pharmacy: migration-special pricing from programs that won’t say who compounds — five minutes of verification is non-negotiable when you’re moving fast, because fast is when it gets skipped. The seamless-switch upsell: quiet molecule swaps (semaglutide continuity marketed as equivalent continuation) — legitimate as an informed choice, misleading as fine print; the trial gap is real and belongs in the open. The gray-market whisper: research-chemical vials and group buys surge after every disruption — the filter file’s counterfeit section is the antidote, and “no prescriber, no pharmacy name, no COA” remains a complete disqualification in any market weather.
The seven-day migration plan
Day one: full export — dose history, fills, terms, billing — into the permanent folder. Day two: coverage check (five minutes; a ~$25 covered-brand outcome ends the shopping). Day three: shortlist three providers across tiers using the value board; run the ten-minute terms read and pharmacy verification on each. Day four: start the chosen intake with your dose history attached; ask two questions in the first message — current corridor time, and whether your maintenance dose continues as-is. Day five: cancel or convert the old account in writing; file the confirmation. Day six: confirm the new pharmacy name on the prescription record; run the lookup. Day seven: update the dose diary with the transition note and the new ship-day, and put the annual review on next year’s calendar — because the file that made this migration calm is the one you’ll want already open at the next market event.
FAQ
Did Hims stop all compounded GLP-1s?
No — the March 2026 settlement ended its compounded tirzepatide; compounded semaglutide continued (~$175/month as of this writing) alongside a branded oral lane. Tirzepatide patients must switch molecules in-house or migrate providers.
How long can I go between tirzepatide doses while switching providers?
Label-consistent missed-dose guidance allows roughly four days past the scheduled day; beyond that, skip-and-resume logic applies and prolonged gaps risk a restart with re-titration — start the new intake two to three weeks before supply runs out.
What does compounded tirzepatide cost after the Hims exit?
Tier-labeled as of August 2026: audited flat plans at $139–$169/month dose-proof; the best on-record independent at $133; famous-name no-commitment lanes near $449; self-published entrants $99–$149 pending verification; covered brand can reach ~$25 with a card, direct-pay brand ~$449+ at maintenance strengths.
Should I take the in-house semaglutide switch instead of migrating?
It’s a legitimate option with an honest trade — head-to-head trials showed roughly a six-point body-weight gap favoring tirzepatide in treatment-naive cohorts. If tirzepatide is working for you, migrating to keep it is the continuity play; the switching file covers the other path.